Twist Bioscience Corp. TWST
NASDAQ · United States · Health Technology
$193.24+7.11 (+3.82%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the pharma stock. But perhaps the more important change was in Foundayo estimates. Guggenheim sharply raised its revenue forecasts for Lilly’s oral obesity drug, […]
A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.
Key TakeawaysAnthropic Ripple: Twist Bioscience stock jumped 16% on Thursday, September 24, after Leerink Partners called the company the single most important beneficiary of Anthropic’s expanding biology research. Split Street: TIKR tracks 13 analysts: 7 buys, 2 outperforms, 3 holds, 1 sell.
Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY). As part of the strategic partnership, Twist will provide antibody characterization data […]
Twist Bioscience (TWST) has surged 493% over 52 weeks, maintaining strong technical momentum. Shares just hit a new all-time high and has a 100% “Buy” technical opinion. However, its RSI of 72.95 and high short interest signal potential overextension. Consensus price targets are well below current levels, suggesting limited upside....
DNA Synthesis Market Accelerates on Precision Medicine, Synthetic Biology and High-Throughput Automation DemandDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "DNA Synthesis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global DNA Synthesis Market to Reach USD 11.5 Billion by 2035, Driven by Synthetic Biology and Precision Medicine The global DNA synthesis market, valued at USD 2.5 billion in 2025, is projecte
Twist traded as high as $163.70 on Thursday and finished the session about 9% higher near $156.
Haemonetics and Twist Bioscience stocks surged to more than five-year highs on Thursday, as fresh growth opportunities drew cheer from Wall Street.
On 16 September 2026, Twist Bioscience announced an agreement with Lilly TuneLab, under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly’s AI/ML drug discovery models. This collaboration effectively plugs Twist’s DNA and antibody capabilities into Lilly’s AI-driven discovery ecosystem, potentially deepening Twist’s role in data-rich, AI-enhanced antibody development workflows across the...
Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]
Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Se
SOUTH SAN FRANCISCO, Calif., September 16, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.
